Sarah Bos

15 General introduction 1 18. Lisman T. Decreased Fibrinolytic Capacity in Cirrhosis and Liver Transplantation Outcomes. 2019;25(3):359–61. 19. Lebreton A, Sinegre T, Pereira B, LamblinG, Duron C, Abergel A. Plasma hypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. J Gastroenterol Hepatol. 2017 Apr;32(4):916–24. 20. Groeneveld D, Porte RJ, Lisman T. Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. Thromb Res. 2014;134(3):753–6. 21. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology. 2005 Mar;41(3):553–8. 22. Youngwon N, Kim JE, Lim HS, Han KS, Kim HK. Coagulation proteins influencing global coagulation assays in cirrhosis: Hypercoagulability in cirrhosis assessed by thrombomodulin-induced thrombin generation assay. Biomed Res Int. 2013;2013. 23. Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M, et al. The risk of venous thromboembolism in patients with cirrhosis. Thromb Haemost. 2016;117(1):139–48. 24. Ageno W, Squizzato A, Togna A, Magistrali F, Mangini M, Fugazzola C, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: A retrospective cohort study. J Thromb Haemost. 2012;10(1):158–60. 25. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: Usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7. 26. Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: Outcome of anticoagulation. Dig Dis Sci. 2013;58(6):1776–80. 27. Stine JG, Shah PM, Cornella SL, Rudnick SR, Ghabril MS, Stukenborg GJ, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta- analysis. World J Hepatol. 2015;7(27):2774–80. 28. Arshad F, Adelmeijer J, Blokzijl H, van den Berg A, Porte R, Lisman T. Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation. F1000Research. 2014 Jul 30;3:1–18. 29. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823. 30. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, BounameauxH, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52. 31. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e531S-e575S. 32. Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55(12):1395–405.